Abstract
Purpose of Review
To define adequate terminology regarding non-superficial or deep cutaneous manifestations of infection by Candida, as well as to describe the most common causal species, clinical manifestations, and treatment options.
Recent Findings
The prevalence and clinical significance of non-albicans Candida species have been increasing. Research has better characterized these emerging fungi.
Summary
Candidiasis ranges from superficial mucocutaneous infections to invasive manifestations, including candidemia and organ involvement. Invasive candidiasis (IC) includes candidemia (Candida in the bloodstream) and deep-seated candidiasis. Risk factors for IC include immunosuppression, critical illness, broad-spectrum antibiotic use, and skin barrier disruptions. Although C. albicans remains the most common species in IC, other species, such as C. tropicalis, C. glabrata, and C. auris, are becoming more prevalent. C. tropicalis is the most commonly isolated species in deep candida infections. Clinical presentations range from ecthyma gangrenosum-like lesions to ulcers, necrosis, and purpura fulminans. This review emphasizes the importance of a high index of suspicion for these infections, particularly in immunocompromised patients. Skin biopsy aids in timely diagnosis and treatment.
Similar content being viewed by others
Data Availability
No datasets were generated or analyzed during the current study.
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis. Nat Rev Dis Primers. 2018;4:18026. https://doi.org/10.1038/nrdp.2018.26.
•• Fang W, Wu J, Cheng M, Zhu X, Du M, Chen C, Liao W, Zhi K, Pan W. Diagnosis of invasive fungal infections: challenges and recent developments. J Biomed Sci. 2023;30(1):42. https://doi.org/10.1186/s12929-023-00926-2. An up-to-date review on diagnostic approaches for invasive mycoses and the mechanisms of antifungal resistance.
• McCarty TP, White CM, Pappas PG. Candidemia and invasive candidiasis. Infect Dis Clin N Am. 2021;35(2):389–413. https://doi.org/10.1016/j.idc.2021.03.007. A comprehensive review of the primary Candida species that play a significant role in the development of candidemia and invasive candidiasis.
•• Oliva A, De Rosa FG, Mikulska M, Pea F, Sanguinetti M, Tascini C, Venditti M. Invasive Candida infection: epidemiology, clinical and therapeutic aspects of an evolving disease and the role of rezafungin. Expert Rev Anti-Infect Ther. 2023;21(9):957–75. https://doi.org/10.1080/14787210.2023.2240956. A recent review on invasive candidiasis epidemiology and razafungin, a novel echinocandin.
Kullberg BJ, Arendrup MC. Invasive candidiasis. N Engl J Med. 2015;373(15):1445–56. https://doi.org/10.1056/NEJMra1315399.
McCarty TP, Pappas PG. Invasive candidiasis. Infect Dis Clin N Am. 2016;30(1):103–24. https://doi.org/10.1016/j.idc.2015.10.013.
Clancy CJ, Nguyen MH. Finding the “missing 50%” of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis. 2013;56(9):1284–92. https://doi.org/10.1093/cid/cit006.
Fang SY, Wei KC, Chen WC, Lee SJ, Yang KC, Wu CS, Sun PL. Primary deep cutaneous candidiasis caused by Candida duobushaemulonii in a 68-year-old man: the first case report and literature review. Mycoses. 2016;59(12):818–21. https://doi.org/10.1111/myc.12540.
Barantsevich N, Barantsevich E. Diagnosis and treatment of invasive candidiasis. Antibiotics (Basel). 2022;11(6):718. https://doi.org/10.3390/antibiotics11060718.
Oberoi JK, Wattal C, Goel N, Raveendran R, Datta S, Prasad K. Non-albicans Candida species in blood stream infections in a tertiary care hospital at New Delhi, India. Indian J Med Res. 2012;136(6):997–1003.
Nurdin RSC, Vitayani S, Amin S, Kadir D, Djamaluddin W, Adriani A. Cutaneous candidiasis caused by Candida kefyr. Pan Afr Med J. 2021;38:178. https://doi.org/10.11604/pamj.2021.38.178.28054.
Leroy O, Gangneux JP, Montravers P, Mira JP, Gouin F, Sollet JP, Carlet J, Reynes J, Rosenheim M, Regnier B, Lortholary O, AmarCand Study Group. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med. 2009;37(5):1612–8. https://doi.org/10.1097/CCM.0b013e31819efac0.
Bae GY, Lee HW, Chang SE, Moon KC, Lee MW, Choi JH, Koh JK. Clinicopathologic review of 19 patients with systemic candidiasis with skin lesions. Int J Dermatol. 2005;44(7):550–5. https://doi.org/10.1111/j.1365-4632.2004.02006.x.
Marak MB, Dhanashree B. Antifungal susceptibility and biofilm production of Candida spp. isolated from clinical samples. Int. J Microbiol. 2018;2018:7495218. https://doi.org/10.1155/2018/7495218.
Rodríguez-Cerdeira C, Gregorio MC, Molares-Vila A, López-Barcenas A, Fabbrocini G, Bardhi B, Sinani A, Sánchez-Blanco E, Arenas-Guzmán R, Hernandez-Castro R. Biofilms and vulvovaginal candidiasis. Colloids Surf B: Biointerfaces. 2019;174:110–25. https://doi.org/10.1016/j.colsurfb.2018.11.011.
Chai LY, Denning DW, Warn P. Candida tropicalis in human disease. Crit Rev Microbiol. 2010;36(4):282–98. https://doi.org/10.3109/1040841X.2010.489506.
Oksuz S, Sahin I, Yildirim M, Gulcan A, Yavuz T, Kaya D, Koc AN. Phospholipase and proteinase activities in different Candida species isolated from anatomically distinct sites of healthy adults. Jpn J Infect Dis. 2007;60(5):280–3.
Leung AY, Chim CS, Ho PL, Cheng VC, Yuen KY, Lie AK, Au WY, Liang R, Kwong YL. Candida tropicalis fungaemia in adult patients with haematological malignancies: clinical features and risk factors. J Hosp Infect. 2002;50(4):316–9. https://doi.org/10.1053/jhin.2002.1194.
Frías-De-León MG, Hernández-Castro R, Vite-Garín T, Arenas R, Bonifaz A, Castañón-Olivares L, Acosta-Altamirano G, Martínez-Herrera E. Antifungal resistance in Candida auris: molecular determinants. Antibiotics (Basel). 2020;9(9):568. https://doi.org/10.3390/antibiotics9090568.
•• Tharp B, Zheng R, Bryak G, Litvintseva AP, Hayden MK, Chowdhary A, Thangamani S. Role of microbiota in the skin colonization of Candida auris. mSphere. 2023;8(1):e0062322. https://doi.org/10.1128/msphere.00623-22. A recent review focuses on C. auris as an emerging pathogen in the context of invasive candidiasis.
Gow NA, van de Veerdonk FL, Brown AJ, Netea MG. Candida albicans morphogenesis and host defence: discriminating invasion from colonization. Nat Rev Microbiol. 2011;10(2):112–22. https://doi.org/10.1038/nrmicro2711.
Shields BE, Rosenbach M, Brown-Joel Z, Berger AP, Ford BA, Wanat KA. Angioinvasive fungal infections impacting the skin: background, epidemiology, and clinical presentation. J Am Acad Dermatol. 2019;80(4):869–880.e5. https://doi.org/10.1016/j.jaad.2018.04.059.
Kim MS, Lee SM, Sung HS, Won CH, Chang S, Lee MW, Choi JH, Moon KC. Clinical analysis of deep cutaneous mycoses: a 12-year experience at a single institution. Mycoses. 2012;55(6):501–6. https://doi.org/10.1111/j.1439-0507.2012.02191.x.
Milner JD, Brenchley JM, Laurence A, Freeman AF, Hill BJ, Elias KM, Kanno Y, Spalding C, Elloumi HZ, Paulson ML, Davis J, Hsu A, Asher AI, O'Shea J, Holland SM, Paul WE, Douek DC. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature. 2008;452(7188):773–6. https://doi.org/10.1038/nature06764.
Lanternier F, Cypowyj S, Picard C, Bustamante J, Lortholary O, Casanova JL, Puel A. Primary immunodeficiencies underlying fungal infections. Curr Opin Pediatr. 2013;25(6):736–47. https://doi.org/10.1097/MOP.0000000000000031.
Lanternier F, Pathan S, Vincent QB, Liu L, Cypowyj S, Prando C, Migaud M, Taibi L, Ammar-Khodja A, Stambouli OB, Guellil B, Jacobs F, Goffard JC, Schepers K, Del Marmol V, Boussofara L, Denguezli M, Larif M, Bachelez H, et al. Deep dermatophytosis and inherited CARD9 deficiency. N Engl J Med. 2013;369(18):1704–14. https://doi.org/10.1056/NEJMoa1208487.
Rouzaud C, Hay R, Chosidow O, Dupin N, Puel A, Lortholary O, Lanternier F. Severe dermatophytosis and acquired or innate immunodeficiency: a review. J Fungi (Basel). 2015;2(1):4. https://doi.org/10.3390/jof2010004.
Ferwerda B, Ferwerda G, Plantinga TS, Willment JA, van Spriel AB, Venselaar H, Elbers CC, Johnson MD, Cambi A, Huysamen C, Jacobs L, Jansen T, Verheijen K, Masthoff L, Morré SA, Vriend G, Williams DL, Perfect JR, Joosten LA, et al. Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med. 2009;361(18):1760–7. https://doi.org/10.1056/NEJMoa0901053.
Lewis RE, Cahyame-Zuniga L, Leventakos K, Chamilos G, Ben-Ami R, Tamboli P, Tarrand J, Bodey GP, Luna M, Kontoyiannis DP. Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study. Mycoses. 2013;56(6):638–45. https://doi.org/10.1111/myc.12081.
Ishikawa H, Yamaguchi Y, Nakajima Y, Miyazaki T, Wada H, Aihara M. Case of widespread purpura due to emboli of Candida parapsilosis. J Dermatol. 2016;43(2):216–7. https://doi.org/10.1111/1346-8138.13177.
Pedraz J, Delgado-Jiménez Y, Pérez-Gala S, Nam-Cha S, Fernández-Herrera J, García-Diez A. Cutaneous expression of systemic candidiasis. Clin Exp Dermatol. 2009;34(1):106–10. https://doi.org/10.1111/j.1365-2230.2007.02524.x.
Beasley K, Panach K, Dominguez AR. Disseminated Candida tropicalis presenting with ecthyma-gangrenosum-like lesions. Dermatol Online J. 2016;22(1) 13030/qt7vg4n68j. https://doi.org/10.5070/D3221029790
• Santarelli IM, Brest A, Juri PJ, Grinspun M, Fernández SI. Lesiones cutáneas asociadas a candidiasis invasiva en un paciente neutropénico con leucemia mieloide aguda [Skin lesions associated with invasive candidiasis in a neutropenic patient with acute myeloid leukemia]. Rev Fac Cien Med Univ Nac Cordoba. 2023;80(2):158–9. https://doi.org/10.31053/1853.0605.v80.n2.38723. One of the latest papers discussing non-superficial cutaneous manifestations in invasive candidiasis.
Xi L, Li X, Zhang J, Lu C, Xie T, Yin R. Good response in a patient with deep-seated subcutaneous ulcer due to Candida species. Mycopathologia. 2007;164(2):77–80. https://doi.org/10.1007/s11046-007-9030-y.
Galimberti RL, Flores V, Gonzalez Ramos MC, Villalba LI. Cutaneous ulcers due to Candida albicans in an immunocompromised patient--response to therapy with itraconazole. Clin Exp Dermatol. 1989;14(4):295–7. https://doi.org/10.1111/j.1365-2230.1989.tb01984.x.
• Caballero JC, Askari E, Carrasco N, Piris MA, Perez de Camino B, Pardo L, Cornago J, Lopez-Lorenzo JL, Llamas P, Solan L. Invasive cutaneous candidiasis, autoimmune hemolytic anemia and pancytopenia: a challenging scenario for Waldenström macroglobulinemia in an elderly patient. Biomedicines. 2023;11(4):1007. https://doi.org/10.3390/biomedicines11041007. This case illustrates an extensive ulcerous presentation of deep cutaneous candidiasis.
Silverman RA, Rhodes AR, Dennehy PH. Disseminated intravascular coagulation and purpura fulminans in a patient with Candida sepsis. Biopsy of purpura fulminans as an aid to diagnosis of systemic Candida infection. Am J Med. 1986;80(4):679–84. https://doi.org/10.1016/0002-9343(86)90824-7.
Ginter G, Rieger E, Soyer HP, Hoedl S. Granulomatous panniculitis caused by Candida albicans: a case presenting with multiple leg ulcers. J Am Acad Dermatol. 1993;28(2 Pt 2):315–7. https://doi.org/10.1016/0190-9622(93)70044-t.
Cortez JL, Tan SY, Abelman R, Chin-Hong P, McCalmont TH, Fox L, Haemel A. Deep cutaneous candidiasis of the lip in a patient with acute myelogenous leukemia. JAAD Case Rep. 2022;27:32–4. https://doi.org/10.1016/j.jdcr.2022.06.039.
Sharon V, Eisen DB, Fung MA. Cutaneous septic emboli from Candida tropicalis. Lancet Infect Dis. 2010;10(9):652. https://doi.org/10.1016/S1473-3099(10)70119-5.
Clancy CJ, Nguyen MH. Diagnosing invasive candidiasis. J Clin Microbiol. 2018;56(5):e01909–17. https://doi.org/10.1128/JCM.01909-17.
. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1–50. https://doi.org/10.1093/cid/civ933. The latest update from the IDSA on the treatment of invasive candidiasis
Ellepola AN, Morrison CJ. Laboratory diagnosis of invasive candidiasis. J Microbiol. 2005;43 Spec No:65-84
Mikulska M, Calandra T, Sanguinetti M, Poulain D, Viscoli C, Third European Conference on Infections in Leukemia Group. The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Crit Care. 2010;14(6):R222. https://doi.org/10.1186/cc9365.
Karageorgopoulos DE, Vouloumanou EK, Ntziora F, Michalopoulos A, Rafailidis PI, Falagas ME. β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis. 2011;52(6):750–70. https://doi.org/10.1093/cid/ciq206.
. Guarana M, Nucci M. Acute disseminated candidiasis with skin lesions: a systematic review. Clin Microbiol Infect. 2018;24(3):246–50. https://doi.org/10.1016/j.cmi.2017.08.016. A systematic review of patients with invasive candidiasis and cutaneous lesions.
Whaley SG, Berkow EL, Rybak JM, Nishimoto AT, Barker KS, Rogers PD. Azole antifungal resistance in Candida albicans and emerging non-albicans Candida species. Front Microbiol. 2017;7:2173. https://doi.org/10.3389/fmicb.2016.02173.
Ham YY, Lewis JS 2nd, Thompson GR 3rd. Rezafungin: a novel antifungal for the treatment of invasive candidiasis. Future Microbiol. 2021;16(1):27–36. https://doi.org/10.2217/fmb-2020-0217.
Desnos-Ollivier M, Bretagne S, Raoux D, Hoinard D, Dromer F. Dannaoui E; European Committee on Antibiotic Susceptibility Testing. Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing. Antimicrob Agents Chemother. 2008;52(9):3092–8. https://doi.org/10.1128/AAC.00088-08.
. Paiva JA, Pereira JM. Treatment of invasive candidiasis in the era of Candida resistance. Curr Opin Crit Care. 2023;29(5):457–62. https://doi.org/10.1097/MCC.0000000000001077. This paper explores both the mechanisms of action of antifungal drugs and the mechanisms of resistance to them.
Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, Bearden DT. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006;43(1):25–31.
. Gonzalez-Lara MF, Ostrosky-Zeichner L. Invasive candidiasis. Semin Respir Crit Care Med. 2020;41(1):3–12. https://doi.org/10.1055/s-0040-1701215. This article underscores the importance of employing step-down therapy when antifungal susceptibility is available.
. Lamoth F. Novel therapeutic approaches to invasive candidiasis: considerations for the clinician. Infect Drug Resist. 2023;16:1087–97. https://doi.org/10.2147/IDR.S375625. A recent systematic review about novel antifungal agents for the treatment of invasive candidiasis.
Pristov KE, Ghannoum MA. Resistance of Candida to azoles and echinocandins worldwide. Clin Microbiol Infect. 2019;25(7):792–8. https://doi.org/10.1016/j.cmi.2019.03.028.
Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A. The global problem of antifungal resistance: prevalence, mechanisms, and management. Lancet Infect Dis. 2017;17(12):e383–92. https://doi.org/10.1016/S1473-3099(17)30316-X.
Arendrup MC, Patterson TF. Multidrug-resistant Candida: epidemiology, molecular mechanisms, and treatment. J Infect Dis. 2017;216(suppl_3):S445–51. https://doi.org/10.1093/infdis/jix131.
. Arastehfar A, Daneshnia F, Hafez A, Khodavaisy S, Najafzadeh MJ, Charsizadeh A, Zarrinfar H, Salehi M, Shahrabadi ZZ, Sasani E, Zomorodian K, Pan W, Hagen F, Ilkit M, Kostrzewa M, Boekhout T. Antifungal susceptibility, genotyping, resistance mechanism, and clinical profile of Candida tropicalis blood isolates. Med Mycol. 2020;58(6):766–73. https://doi.org/10.1093/mmy/myz124. This review provides insights into the resistance mechanisms exhibited by C. tropicalis and also assesses its susceptibility to antifungal agents.
Author information
Authors and Affiliations
Contributions
GF and SB wrote the main manuscript. MG, AB, AB, and JD helped review the manuscript and provided additional information. All authors reviewed the manuscript.
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare no competing interests.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human participants or animals performed by any of the authors.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Figueroa-Ramos, G., Bermúdez-Rodríguez, S.P., Gatica-Torres, M. et al. Non-superficial Cutaneous Manifestations by Candida Species. Curr Fungal Infect Rep 18, 51–59 (2024). https://doi.org/10.1007/s12281-024-00485-5
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12281-024-00485-5